PubRank

L Hiller

Author PubWeight™ 20.06‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Questioning specialists' attitudes to breast cancer follow-up in primary care. Ann Oncol 2007 2.19
2 A prospective double blind placebo-controlled randomized trial of ultrasound in the physiotherapy treatment of shoulder pain. Rheumatology (Oxford) 2007 1.39
3 A study of five candidate genes in Parkinson's disease and related neurodegenerative disorders. European Study Group on Atypical Parkinsonism. Neurology 1999 1.25
4 Review of second-line chemotherapy for advanced gastric adenocarcinoma. Clin Oncol (R Coll Radiol) 2005 1.20
5 Preferential retention of codon 72 arginine p53 in squamous cell carcinomas of the vulva occurs in cancers positive and negative for human papillomavirus. Cancer Res 2000 1.14
6 A central review of histopathology reports after breast cancer neoadjuvant chemotherapy in the neo-tango trial. Br J Cancer 2013 1.11
7 What is the optimal distal resection margin for esophageal carcinoma? Ann Thorac Surg 2000 0.99
8 The cost-effectiveness of adjuvant chemotherapy for early breast cancer: A comparison of no chemotherapy and first, second, and third generation regimens for patients with differing prognoses. Eur J Cancer 2011 0.97
9 Impaired endothelial function in systemic lupus erythematosus. Lupus 2007 0.93
10 Observer variability among colposcopists from the West Midlands region. Br J Obstet Gynaecol 1997 0.93
11 Proapoptotic genes BAX and CD40L are predictors of survival in transitional cell carcinoma of the bladder. Br J Cancer 2003 0.90
12 tAnGo: a randomised phase III trial of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy for early breast cancer: a prospective pulmonary, cardiac and hepatic function evaluation. Br J Cancer 2008 0.90
13 Accuracy of unidimensional and volumetric ultrasound measurements in predicting good pathological response to neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Res Treat 2011 0.89
14 Development and psychometric testing of a symptom index for pelvic organ prolapse. J Obstet Gynaecol 2006 0.87
15 BCL2 expression predicts survival in patients receiving synchronous chemoradiotherapy in advanced transitional cell carcinoma of the bladder. Oncol Rep 2003 0.86
16 NEAT: National Epirubicin Adjuvant Trial--toxicity, delivered dose intensity and quality of life. Br J Cancer 2008 0.85
17 The effect of biological effective dose on time to symptom progression in metastatic renal cell carcinoma. Clin Oncol (R Coll Radiol) 2003 0.83
18 The SDF-1 G > A polymorphism at position 801 plays no role in multiple myeloma but may contribute to an inferior cause-specific survival in chronic lymphocytic leukemia. Leuk Lymphoma 2006 0.80
19 Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials. Br J Cancer 2012 0.79
20 MRI study of regional variations of pharyngeal wall compliance in cats. J Appl Physiol (1985) 1998 0.78
21 The use of an anabolic steroid (nandrolone decanoate) to improve nutritional status after esophageal resection for carcinoma. Dis Esophagus 1999 0.76
22 ECF in gastric cancer. Clin Oncol (R Coll Radiol) 2004 0.75
23 Research in Music with Electronics. Science 1965 0.75